|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ignition and combustion of aluminum/mag nesium alloy particles in O2 at high pressures显示文摘 | Ted A R Rodney L B | | Combustion and Flame0，92，： | 2 |
| 2 | Analysis and extensions of the Frankle-McCann retinex algorithm 显示文摘 | Ted J C Farhan A B | 2004 | Journal of Electronic Image2004，13，1： | 1 |
| 3 | , a critical role of IRF-I显示文摘 | JARUGA B HONG F KIM W H et aL IFN-gamma/ STAT 1 acts as a proinflamrnatory signal in T cell-media- ted hepatitis via induction of multiple chemokines and ad- hesion molecules | 2004 | Am J Physiol Gastrointest Liver Physiol2004，287，： | 1 |
| 4 | Measuring core- stability显示文摘 | Wendell P L Ted A B Laura H G | 2005 | J Strength Condres2005，19，3： | 1 |
| 5 | Ignition and combustion of aluminum/magnesium alloy particles in O2 at high pressures显示文摘 | Ted A R Rodney L B | 1993 | Combustion and Flame1993，92，： | 1 |
| 6 | Wind erosion quantity and quality of an antic haplustoll of the semi-arid pampas of Argentina显示文摘 | DANIEL E B TED M Z SERGIO A | 2007 | Journal of Arid Environments2007，69，： | 1 |
| 7 | Measuring core stability显示文摘 | WENDELLPL TED A B LAURA H G | | 0，，03： | 1 |
| 8 | Analysis and extensions of the Frankle_McCann Retinex algorithm 显示文摘 | TED J C FARHAN A B | 2004 | Journal of Elec- tronic Imaging2004，13，1： | 1 |
| 9 | Monitoring with a modified robel pole on meadows in the central black hills of south Dakota显示文摘 | Daniel W U Ted A B | 2007 | Western North American Naturalist2007，67，1： | 1 |
| 10 | How MulWnationa Firms Can Profit from Sophisticated Transfer Pricing 8tratedfes显示文摘 | Mrtfnson Otto B Enlebrecht Ted D a Mithell Carla | 2001 | The Journal of Corporate Acceuntind a Finance2001，，10： | 1 |
| 11 | Measuring core stability显示文摘 | WENDELL P L TED A B LAURA H G | 2005 | J Strength Conditioning Res2005，19，3： | 1 |
| 12 | Competing risks of death in younger and older postmenopausal breast cancer patients显示文摘AIM: To show a new paradigm of simultaneously testing whether breast cancer therapies impact other causes of death. METHODS: MA.14 allocated 667 postmenopausal women to 5 years of tamoxifen 20 mg/daily ± 2 years of octreotide 90 mg, given by depot intramuscular injections monthly. Event-free survival was the primary endpoint of MA.14; at median 7.9 years, the tamoxifen+octreotide and tamoxifen arms had similar event-free survival(P = 0.62). Overall survival was a secondary endpoint, and the two trial arms also had similar overall survival(P = 0.86). We used the median 9.8 years follow-up to examine by intention-to-treat, the multivariate time-to-breast cancer-specific(Br Ca) and other cause(OC) mortality with log-normal survival analysis adjusted by treatment and stratification factors. We tested whether baseline factors including Insulin-like growth factor 1(IGF1), IGF binding protein-3, C-peptide, body mass index, and 25-OH vitamin D were associated with(1) all cause mortality, and if so; and(2) cause-specific mortality. We also fit step-wise forward cause-specific adjusted models.RESULTS: The analyses were performed on 329 patients allocated tamoxifen and 329 allocated tamoxifen+octreotide. The median age of MA.14 patients was 60.1 years: 447(82%) < 70 years and 120(18%) ≥ 70 years. There were 170 deaths: 106(62.3%) BrC a; 55(32.4%) OC, of which 24 were other malignancies, 31 other causes of death; 9(5.3%) patients with unknown cause of death were excluded from competing risk assessments. BrC a and OC deaths were not significantly different by treatment arm(P = 0.40): tamoxifen patients experienced 50 BrC a and 32 OC deaths, while tamoxifen + octreotide patients experienced 56 Br Ca and 23 OC deaths. Proportionately more deaths(P = 0.004) were from BrC a for patients< 70 years, where 70% of deaths were due to Br Ca, compared to 54% for those ≥ 70 years of age. The proportion of deaths from OC increased with increasing body mass index(BMI)(P = 0.02). Higher pathologic T and N were associated with more BrC a deaths(P < 0.0001 and 0.002, respectively). The cumulative hazard plot for Br Ca and OC mortality indicated the concurrent accrual of both types of death throughout followup, that is the existence of competing risks of mortality. MA.14 therapy did not impact mortality(P = 0.77). Three baseline patient and tumor characteristics were differentially associated with cause of death: older patients experienced more OC(P = 0.01) mortality; patients with T1 tumors and hormone receptor positive tumors had less BrC a mortality(respectively, P = 0.01, P = 0.06). Additionally, step-wise cause-specific models indicated that patients with node negative disease experienced less BrC a mortality(P = 0.002); there was weak evidence that, lower C-peptide(P = 0.08) was associated with less BrC a mortality, while higher BMI(P = 0.01) was associated with worse OC mortality.CONCLUSION: We demonstrate here a new paradigm of simultaneous testing of therapeutics directed at multiple diseases for which postmenopausal women are concurrently at risk. Octreotide LAR did not significantly impact breast cancer or other cause mortality, although different baseline factors influenced type of death. | Judy-Anne W Chapman Kathleen I Pritchard Paul E Goss James N Ingle Hyman B Muss Susan F Dent Ted A Vandenberg Brian Findlay Karen A Gelmon Carolyn F Wilson Lois E Shepherd Michael N Pollak | 2014 | World Journal of Clinical Oncology2014，5，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员